Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Other Non Operating Income (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Other Non Operating Income for 8 consecutive years, with -$304000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non Operating Income rose 83.69% year-over-year to -$304000.0, compared with a TTM value of $2.3 million through Sep 2025, up 105.69%, and an annual FY2024 reading of $332000.0, down 40.07% over the prior year.
  • Other Non Operating Income was -$304000.0 for Q3 2025 at X4 Pharmaceuticals, down from $2.6 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $25.2 million in Q3 2023 and bottomed at -$24.9 million in Q4 2023.
  • Average Other Non Operating Income over 5 years is -$596315.8, with a median of -$31000.0 recorded in 2021.
  • The sharpest move saw Other Non Operating Income surged 5806.12% in 2023, then crashed 11282.93% in 2024.
  • Year by year, Other Non Operating Income stood at -$330000.0 in 2021, then soared by 748.79% to $2.1 million in 2022, then tumbled by 1264.64% to -$24.9 million in 2023, then soared by 99.43% to -$143000.0 in 2024, then tumbled by 112.59% to -$304000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for XFOR at -$304000.0 in Q3 2025, $2.6 million in Q2 2025, and $105000.0 in Q1 2025.